Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elan Unit’s Acquisition Brings Diversification, Cash Flow, To Alkermes

Executive Summary

Alkermes Inc's acquisition of Elan Corp.'s Elan Drug Technology, announced May 9, more than doubles the revenues of one of the biopharma industry's most successful reformulation companies, and provides it with additional cash flow it needs to pursue a slate of innovative compounds it is developing.

Related Content

With Alkermes’ Transition Well Under Way, Commercial Expansion Is Next
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
Alkermes After Elan: A Slow Start But A Maturing Pipeline
As Majority Of U.S. Patients Tested For JCV, Tysabri Sales Rise, Elan Says
Alkermes' Top Management Takes Its Transformative Message On The Road
Proteostasis Teams Up With Elan In $50M Neurodegenerative Collaboration
Deals Of The Week: Shire/Heptares, Allos/Mundipharma, Pfizer/Zealand
Alkermes Buys Size With Purchase Of Elan Drug Delivery Unit
A Solution For Elan: It Strikes A Deal With J&J On Key Alzheimer's Assets





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts